Actinium Pharmaceuticals (ATNM) Total Liabilities (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Total Liabilities of $43.1 million for Q1 2026, little changed year-over-year from $43.0 million in Q1 2025, and down 1.84% quarter-over-quarter from $43.9 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Total Liabilities (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Total Liabilities for 17 consecutive years, with $43.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities changed 0.42% year-over-year to $43.1 million; the TTM figure through Mar 2026 stood at $43.1 million (changed 0.42% YoY), while the FY2025 annual figure was $43.9 million, changed 0.45% from the prior year.
- Total Liabilities eased to $43.1 million in Q1 2026 per ATNM's latest filing, from $43.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $47.7 million in Q4 2022 and bottomed at $5.7 million in Q1 2022.
- Historically, Total Liabilities has averaged $42.3 million across 5 years, with a median of $44.1 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 1002.88% — and 2023, when it retreated 5.54%.
- Actinium Pharmaceuticals' Total Liabilities stood at $47.7 million in 2022, then declined by 5.54% to $45.1 million in 2023, then fell by 2.05% to $44.1 million in 2024, then slipped by 0.45% to $43.9 million in 2025, then declined by 1.84% to $43.1 million in 2026.
- Business Quant data shows ATNM's Total Liabilities at $43.1 million in Q1 2026, $43.9 million in Q4 2025, and $42.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | 9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.86 Mn |
| Mar 31, 2026 | 43.13 Mn |
| Dec 31, 2025 | 43.94 Mn |
| Sep 30, 2025 | 42.37 Mn |
| Jun 30, 2025 | 44.00 Mn |
| Mar 31, 2025 | 42.95 Mn |
| Dec 31, 2024 | 44.14 Mn |
| Sep 30, 2024 | 43.91 Mn |
| Jun 30, 2024 | 46.03 Mn |
| Mar 31, 2024 | 44.50 Mn |
| Dec 31, 2023 | 45.07 Mn |
| Sep 30, 2023 | 45.36 Mn |
| Jun 30, 2023 | 45.97 Mn |
| Mar 31, 2023 | 44.82 Mn |
| Dec 31, 2022 | 47.71 Mn |
| Sep 30, 2022 | 45.56 Mn |
| Jun 30, 2022 | 43.62 Mn |
| Mar 31, 2022 | 5.73 Mn |
| Dec 31, 2021 | 6.84 Mn |
| Sep 30, 2021 | 4.19 Mn |